会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 91. 发明申请
    • COMPOSITIONS AND METHODS FOR LEUKOCYTE-TARGETING MULTI-VALENT IMAGING PROBES
    • 用于低成本定位多成像成像探针的组合物和方法
    • US20130144035A1
    • 2013-06-06
    • US13642670
    • 2011-04-21
    • Dongfeng PanStuart S. BerrYi Zhang
    • Dongfeng PanStuart S. BerrYi Zhang
    • A61K51/08
    • A61K51/088A61K49/0002A61K49/0034A61K51/06
    • The present application discloses a new multivalent peptide ligand specifically targeting polymorphonuclear leukocytes (PMNs) with favorable pharmacological parameters to monitor sites of inflammation for imaging. The detailed synthesis, characterization, and pharmacological evaluation of the ligands are reported here. Two separate peptide binding ligands for formyl peptide and tuftsin receptors were chosen to link together based on the high expression levels of the two receptors on activated PMNs The heterobivalency and pegylated links were incorporated in the structural design to improve the sensitivity of the detection and to improve the bioavailability along with blood clearance profile, respectively. Two chemical constructs: cFLFLF-(PEG)n-TKPPR-99mTc (n=4, 12) were evaluated in vitro with human PMNs for binding affinity and bioavailability. As a result, FLFLF-(PEG)12-TKPPR99mTc was found to have more favorable pharmacological properties and was therefore used for further in vivo studies. Preliminary in vivo assessment of the agent was performed using Single Gamma Emission Computed Tomography (SPECT) imaging of a mouse model of ear inflammation. The results of these studies indicate cFLFLF-(PEG)12-TKPPR-99mTc may be a desirable imaging agent for binding to PMNs to identify sites of inflammation by SPECT.
    • 本申请公开了一种特异靶向多形核白细胞(PMN)的新型多价肽配体,具有良好的药理学参数,用于监测成像的炎症部位。 这里报道了配体的详细合成,表征和药理学评估。 基于激活的PMN上的两种受体的高表达水平,选择两种单独的用于甲酰肽和簇状蛋白受体的肽结合配体连接在一起。将异源和聚乙二醇化的链接并入结构设计中,以提高检测的灵敏度和改善 分别具有生物利用度和血液清除曲线。 两种化学构建体:cFLFLF-(PEG)n-TKPPR-99mTc(n = 4,12)在体外用人PMNs进行了评估,用于结合亲和力和生物利用度。 结果发现FLFLF-(PEG)12-TKPPR99mTc具有更好的药理学特性,因此用于进一步的体内研究。 使用单发伽马发射计算机断层扫描(SPECT)成像小鼠耳炎的模型进行药物的初步体内评估。 这些研究的结果表明,cFLFLF-(PEG)12-TKPPR-99mTc可能是用于结合PMN的理想显像剂,以通过SPECT鉴定炎症部位。
    • 93. 发明申请
    • SELF-SUSTAINED FLUIDIC DROPLET CASSETTE AND SYSTEM FOR BIOCHEMICAL ASSAYS
    • 自主持续流体液体和生物化学测定系统
    • US20130096035A1
    • 2013-04-18
    • US13805625
    • 2011-07-26
    • Tza-Huei WangSeungkyung ParkSamuel YangYi Zhang
    • Tza-Huei WangSeungkyung ParkSamuel YangYi Zhang
    • C12Q1/68
    • C12Q1/686C12Q1/6844C12Q2565/629
    • A fluidic cartridge for biochemical assays includes a cartridge body defining a first droplet region and a second droplet region with a droplet restraining barrier therebetween. The droplet restraining barrier has a gap between the first and the second droplet regions. The fluidic cartridge also includes a first droplet dispensed in the first droplet region. The first droplet includes a plurality of magnetic particles dispersed therein. The fluidic cartridge also includes a second droplet disposed in the second droplet region. The plurality of magnetic particles are sufficiently small to be drawn through the gap between the first and second droplet regions when compelled by an applied magnetic field, and the first droplet is restrained by the restraining barrier while the plurality of magnetic particles are drawn through the gap. A biochemical assay system includes a stage adapted to receive a fluidic cartridge, and a magnetic control assembly that includes a magnet. The magnet of the magnetic control assembly is movable to direct motion of magnetic particles contained within the fluidic cartridge.
    • 用于生物化学测定的流体盒包括限定第一液滴区域的盒体和在其间具有液滴限制屏障的第二液滴区域。 液滴限制屏障在第一和第二液滴区域之间具有间隙。 流体盒还包括分配在第一液滴区域中的第一液滴。 第一液滴包括分散在其中的多个磁性颗粒。 流体盒还包括设置在第二液滴区域中的第二液滴。 当被施加的磁场强迫时,多个磁性颗粒足够小以便被吸入第一和第二液滴区域之间的间隙,并且第一液滴被约束屏障约束,同时多个磁性颗粒被吸引通过间隙 。 生物化学测定系统包括适于接收流体盒的阶段和包括磁体的磁性控制组件。 磁性控制组件的磁体可移动以引导包含在流体盒内的磁性颗粒的运动。
    • 98. 发明授权
    • Light source driving circuit with low operating output voltage
    • 光源驱动电路,工作输出电压低
    • US08334660B2
    • 2012-12-18
    • US12783484
    • 2010-05-19
    • Eric LiChun LuYi Zhang
    • Eric LiChun LuYi Zhang
    • G05F1/00H05B37/02H05B39/04H05B41/36H05B39/02H05B37/00H05B39/00H05B41/00
    • H05B33/0827
    • A driving circuit for regulating current in a light source using a tracking component. The tracking component detects the voltage difference between an input node in the input stage and an output node in the output stage. The input stage is connected to a current source and includes an input transistor. The output stage is connected to the light source and includes an output transistor. The tracking component generates an output that controls the input and output transistors based on the voltage difference between the input node and the output node so that the voltage at the input node tracks the voltage at the output node. By using the tracking component, the LED driver can achieve accurate current control through one output transistor instead of cascaded transistors, resulting in lower output operating voltage and reduced power dissipation of the LED driver. Further, the tracking component is intermittently operated or shared across different channels to reduce energy consumption of the LED driver.
    • 一种用于使用跟踪部件调节光源中的电流的驱动电路。 跟踪组件检测输入级中的输入节点与输出级中的输出节点之间的电压差。 输入级连接到电流源并包括输入晶体管。 输出级连接到光源并包括输出晶体管。 跟踪组件产生输出,其基于输入节点和输出节点之间的电压差来控制输入和输出晶体管,使得输入节点处的电压跟踪输出节点处的电压。 通过使用跟踪组件,LED驱动器可以通过一个输出晶体管而不是级联晶体管实现精确的电流控制,从而降低输出工作电压并降低LED驱动器的功耗。 此外,跟踪部件在不同的通道间歇地操作或共享以减少LED驱动器的能量消耗。
    • 100. 发明申请
    • HEART FAILURE DETECTION WITH A SEQUENTIAL CLASSIFIER
    • 心脏故障检测与序列分类器
    • US20120157856A1
    • 2012-06-21
    • US13306343
    • 2011-11-29
    • Qi AnYi Zhang
    • Qi AnYi Zhang
    • A61B5/02A61B5/053A61B5/0205
    • A61B5/0816A61B5/0205A61B5/024A61B5/0538A61B7/006A61B7/04G06F19/3418G06F19/3481G16H50/20
    • A system and method for automatically analyzing heart failure in a patient, including collecting physiological data from a patient using at least a first sensor and a second sensor to collect two or more sensor measurements, and calculating a first composite value based on at least a first sensor measurement wherein the first composite value is an indication of a likelihood that the patient's heart failure status has changed. If the first composite value is outside of a first specified range, then a second composite value is calculated based on at least a second sensor measurement, wherein the second composite value is an indication of a likelihood that the patient's heart failure status has changed. If the second composite value is outside of a second specified range, then an alert of change in heart failure status is generated.
    • 一种用于自动分析患者心力衰竭的系统和方法,包括使用至少第一传感器和第二传感器从患者收集生理数据以收集两个或更多个传感器测量值,以及基于至少第一 传感器测量,其中第一复合值是患者的心力衰竭状态已经改变的可能性的指示。 如果第一复合值在第一指定范围之外,则基于至少第二传感器测量来计算第二复合值,其中第二复合值是患者的心力衰竭状态已经改变的可能性的指示。 如果第二个复合值超出第二个指定范围,则会产生心力衰竭状态变化警报。